Results 221 to 230 of about 53,090 (292)

An Unusual Case of Classic Hodgkin Lymphoma With Strong Expression of B‐Cell Markers

International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski, Sorin Selegean, Allam Shawwa, David M. Conrad   +3 more
wiley   +1 more source

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators

Transplant Infectious Disease, EarlyView.
ABSTRACT Toxoplasmosis has long been recognized as a serious complication in immunocompromised host, particularly those with advanced HIV/AIDS, hematopoietic stem‐cell transplantation (HSCT), solid‐organ transplant (SOT), and hematological malignancies. The rapid expansion of targeted immunomodulators, including chimeric antigen receptor T‐cell (CAR‐T)
Joy Mouanes‐Abelin, Christelle Pomares, José G. Montoya, Morgane Pondrom, Lucille DE MARIA, Andrea J. Zimmer, Carlos A. Gomez   +6 more
wiley   +1 more source

Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options. [PDF]

Hematol Transfus Cell Ther
Roshandel E, Lasemi MV, Mehravar M, Salimi M, Majidi M, Mohammadali F, Seraji HR, Hajifathali A.   +7 more
europepmc   +1 more source

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. [PDF]

Nat Commun
Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, Pernikoff S, Yahya K, Stevens-Ayers T, Dasgupta S, Cowan AJ, Green DJ, Gauthier J, Till BG, Gardner RA, Shadman M, Bleakley M, Boeckh M, Boonyaratanakornkit J, Turtle CJ, Hill JA.   +20 more
europepmc   +1 more source

Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response

Transfusion, EarlyView.
Abstract Background Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3+ T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Hanna Kuhn, Felix Korell, Angela Hückelhoven‐Krauss, Brigitte Neuber, Miriam Stenzinger, Anita Ludwig‐Husemann, Maria‐Luisa Schubert, Patrick Derigs, Kiavasch Farid, Tim Sauer, Sandra Sauer, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt   +14 more
wiley   +1 more source

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences. [PDF]

Front Immunol
Schwingen NR, Meretuk L, Aigner M, Kretschmann S, Scholz JK, Gsottberger F, Harrer DC, Dingfelder J, Lutzny-Geier G, Kharboutli S, Mackensen A, Müller F, Völkl S.   +12 more
europepmc   +1 more source

Dendritic cell‐specific hypoxia‐inducible factor‐1α deficiency protects mice from recurrent retroviral infection

Experimental Physiology, EarlyView.
Abstract Antigen‐processing and ‐presenting cells play a pivotal role in initiation of the antiviral immune response. The cellular adaption of dendritic cells to reduced oxygen and nutrition levels at the site of infection is regulated predominantly by the transcription factor complex hypoxia‐inducible factor‐1 (HIF‐1).
Timm Schreiber, Yvonne Hüsecken, Claudia Lodewick, Simone Schimmer, Gennadiy Zelinskyy, Ulf Dittmer, Kathrin Sutter, Joachim Fandrey, Sandra Winning   +8 more
wiley   +1 more source

CD72 downregulation is associated with increased CD5+ B cell proliferation and IL-10 production via ERK/Syk signaling in chronic HBV infection-associated liver disease. [PDF]

Virus Res
Li B, Zhao L, Zhu Q, Xie S.
europepmc   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases. [PDF]

Intractable Rare Dis Res
Fang X, Wei R, Zhu W, Hu Y, Liang H.
europepmc   +1 more source